Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. (3rd October 2019)

• Record Type: Journal Article
• Authors: Pye, Anita; Turner, Alice M
• Is Part Of: Expert opinion on investigational drugs. Volume 28:Number 10(2019)
• Page Start: 891
• Page End: 902
• Publication Date: 2019-10-03
• Subjects: Alpha-1 antitrypsin deficiency -- chronic obstructive pulmonary disease -- emphysema -- cirrhosis -- clinical trials; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2019.1672656
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Alpha-1 antitrypsin deficiency (AATD) is most often associated with chronic lung disease, early onset emphysema, and liver disease. The standard of care in lung disease due to AATD is alpha-1 antitrypsin augmentation but there are several new and emerging treatment options under investigation for both lung and liver manifestations. Areas covered : We review therapeutic approaches to lung and liver disease in alpha-1 antitrypsin deficiency (AATD) and the agents in clinical development according to their mode of action. The focus is on products in clinical trials, but data from pre-clinical studies are described where relevant, particularly where progression to trials appears likely. Expert opinion : Clinical trials directed at lung and liver disease separately are now taking place. Multimodality treatment may be the future, but this could be limited by treatment costs. The next 5–10 years may reveal new guidance on when to use therapeutics for slowing disease progression with personalized treatment regimes coming to the forefront.